Vitamin B-6 Dependency Syndromes
- Author: Anjali Parish, MD; Chief Editor: Jatinder Bhatia, MBBS more...
Background
Although rare, pyridoxine-dependent seizure (PDS) is a recognized cause of intractable seizures in neonates, psychomotor developmental delay, and, sometimes, death in untreated patients.[1, 2, 3, 4] Hunt et al first described PDS in 1954.[5, 1, 6] Since then, fewer than 100 cases have been reported worldwide.[1, 3] Later onset seizures due to pyridoxine deficiency have been reported.[1, 7] The 2 types of presentations are classic and atypical. The classic presentation consists of intractable seizures that appear within hours of birth and are resistant to conventional anticonvulsants. The seizures rapidly respond to administration of parenteral pyridoxine.[1] A trial of pyridoxine is recommended in all seizures that have no clear etiology and occur before the child is aged 18 months.[7]
PDS is probably an underdiagnosed and underreported condition. All medical specialists should be aware of its existence and potentially favorable outcome.[1] Lifelong supplementation of pyridoxine is required.[1, 3]
Vitamin B-6 (pyridoxine)
- Pyridoxine is water-soluble.
- Sources include meat, nuts, and whole-grain products (especially wheat).
- Deficiency usually occurs in conjunction with inadequate intake of other B vitamins due to poor diet or malabsorption states.
- Isolated pyridoxine dependency can occur during treatment with isoniazid, which is a pyridoxine antagonist.
- Pyridoxine requirements are increased in the presence of other drugs, including penicillamine, contraceptive steroids, and hydralazine.
- Clinical features of deficiency in young infants include abnormal CNS activity (eg, irritability, aggravated startle response, seizures) and GI distress (eg, distension, vomiting, diarrhea).
- Other manifestations include anemia, peripheral neuropathy, and dermatitis.
- Treatment consists of pyridoxine 5 mg intramuscularly followed by 0.5 mg per day orally for 2 weeks. Correct dietary deficiency.
- Consider pyridoxine dependency in the differential diagnosis of neonatal seizures when other more common causes have been eliminated. Rapid treatment with pyridoxine, 100 mg intramuscularly, is recommended.
The recommended daily dietary intake for pyridoxine is as follows:
- Infants aged 0-6 months - 0.25 mg/d
- Infants aged 7-12 months - 0.45 mg/d
- Children aged 1-3 years - 0.6-0.9 mg/d
- Children aged 4-7 years - 0.8-1.3 mg/d
- Boys aged 8-11 years - 1.1-1.6 mg/d
- Boys aged 12-15 years - 1.4-2.1 mg/d
- Boys aged 16-18 years - 1.5-2.2 mg/d
- Girls aged 8-11 years - 1-1.5 mg/d
- Girls aged 12-15 years - 1.2-1.8 mg/d
- Girls aged 16-18 years - 1.1-1.6 mg/d
Pathophysiology
PDS is an autosomal recessive inborn disorder of metabolism.[1, 7] Some studies suggest that, as well as seizure activity, the neurobehavioral phenotype of the defective gene in PDS may include cognitive and other neuropsychologic impairment.[6] Some suggest that PDS is possibly caused by a glutamic acid decarboxylase (GAD) abnormality;[8] however, genetic analysis of GAD in affected families has not revealed any defects in this gene.[9, 10]
Epidemiology
Frequency
United States
The frequency of PDS in the United States is unknown. Fewer than 100 cases have been reported in the literature; thus, the full range of symptomatology is unknown.[6]
International
Burd et al reports prevalence data of 1 per 20,000-100,000 live births.[6] Data from the United Kingdom suggest a very low prevalence. A birth incidence of 1 in 783,000 and a point of prevalence of 1 in 687,000 (for definite and probable cases in children < 16 y) have been reported from the United Kingdom and the Republic of Ireland in 1999.[1, 6] In the Netherlands, birth incidence has been reported as 1:396,000 for definite and probable cases of PDS.[11]
Mortality/Morbidity
The literature has not reported mortality and morbidity rates.
Race
No particular race has been identified as more or less susceptible to the condition. Studies have mostly come from the United Kingdom because of misdiagnosis in less developed countries. In 2001, Gupta et al reported that PDS is underdiagnosed and underreported in India.[1]
Sex
The literature has not identified sex differences in susceptibility to PDS.
Age
Most reported cases have been in infants or young children.[1, 2, 7, 3] Outcomes of PDS in older children have rarely been reported.
Gupta VK, Mishra D, Mathur I, Singh KK. Pyridoxine-dependent seizures: a case report and a critical review of the literature. J Paediatr Child Health. Dec 2001;37(6):592-6. [Medline].
Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol. Jun 2001;43(6):416-20. [Medline].
Yoshikawa H, Abe T, Oda Y. Pyridoxine-dependent seizures in an older child. J Child Neurol. Oct 1999;14(10):687-90. [Medline].
Gerlach AT, Thomas S, Stawicki SP, Whitmill ML, Steinberg SM, Cook CH. Vitamin B6 deficiency: a potential cause of refractory seizures in adults. JPEN J Parenter Enteral Nutr. Mar 2011;35(2):272-5. [Medline].
Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. Feb 1954;13(2):140-5. [Medline].
Burd L, Stenehjem A, Franceschini LA, Kerbeshian J. A 15-year follow-up of a boy with pyridoxine (vitamin B6)-dependent seizures with autism, breath holding, and severe mental retardation. J Child Neurol. Nov 2000;15(11):763-5. [Medline].
Grillo E, da Silva RJ, Barbato JH Jr. Pyridoxine-dependent seizures responding to extremely low-dose pyridoxine. Dev Med Child Neurol. Jun 2001;43(6):413-5. [Medline].
Kuo MF, Wang HS. Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine. Pediatr Neurol. Feb 2002;26(2):146-7. [Medline].
Kure S, Sakata Y, Miyabayashi S, et al. Mutation and polymorphic marker analyses of 65K- and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy. J Hum Genet. 1998;43(2):128-31. [Medline].
Battaglioli G, Rosen DR, Gospe SM Jr, Martin DL. Glutamate decarboxylase is not genetically linked to pyridoxine-dependent seizures. Neurology. Jul 25 2000;55(2):309-11. [Medline].
Been JV, Bok LA, Andriessen P, Renier WO. Epidemiology of pyridoxine dependent seizures in the Netherlands. Arch Dis Child. Dec 2005;90(12):1293-6. [Medline].
Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child. Nov 1999;81(5):431-3. [Medline].
Baxter P. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed. Sep 2000;83(2):F163. [Medline].
Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat. Jan 2007;28(1):19-26. [Medline].
Kanno J, Kure S, Narisawa A, et al. Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab. Aug 2007;91(4):384-9. [Medline].
Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. Sep-Oct 2011;104(1-2):48-60. [Medline].
Hasumi H, Kamiyama Y, Nakasora S, Yamamoto Y, Hara M, Fujita Y. Cerebrospinal fluid and serum levels of vitamin B6 in status epilepticus children. Brain Dev. Aug 2011;33(7):580-8. [Medline].
Ohtsuka Y, Ogino T, Asano T, et al. Long-term follow-up of vitamin B(6)-responsive West syndrome. Pediatr Neurol. Sep 2000;23(3):202-6. [Medline].
Hindley D, Huyton M. Pyridoxine dependent and pyridoxine responsive seizures. Arch Dis Child. Jan 2001;84(1):91-2. [Medline].

